In-Home Injection Training

Licensed nurses are available throughout the country to teach adult patients how to self-inject Acthar in the privacy of their own home. Healthcare providers who think their patients can benefit from an in-home training session can request one by calling 1-877-463-88031-877-463-8803.

In-home injection training services will be provided at no cost and are made available through support from Mallinckrodt.

Requesting in-home injection training services for your patient is easy

Step 1

Initial and date the in-home injection training section of the Referral/Prescription Form.

Step 2

Fax the Referral/Prescription Form as you normally would to 1-877-221-9505.

Step 3

As soon as Acthar is ready for shipment from the Specialty Pharmacy to your patient's home, the selected home health agency in your patient's area will contact him or her to set up the injection training visit. During the training visit the nurse will:

  • Review the injection materials and supplies with your patient and his or her care partner
  • Prepare the medication and supplies for the Acthar injection
  • Demonstrate the injection process. (The nurse will show the patient how to extract the medication from the vial and where to inject, but the patient or care partner will actually perform the injection—the nurse will not inject the patient)
  • Review proper disposal and storage procedures
  • Answer any questions about the injection

Frequently Asked Questions about in-home injection training services

What qualifications must the nurse meet?
All of the nurses are carefully screened with background checks and investigations of credentials. They must maintain their professional licensing or certification, pass a thorough skills competency program, and participate in ongoing education programs. Additionally, the patient will receive in the mail Acthar-specific injection training guides and product information prior to the injection training visit as additional support for the nurse.
Are all injection supplies and equipment provided by the visiting nurse?
No. Your patient will receive Acthar and the necessary injection supplies from the Specialty Pharmacy as he or she normally would.
Does insurance pay for in-home injection training services?
In-home injection training services will be provided at no cost and are made available through support from Mallinckrodt.
How quickly will the injection services be scheduled?
Once your patient's Acthar prescription is ready to ship from the Specialty Pharmacy, the selected home health agency will work to schedule the visit at a time that is most convenient for your patient. Typically, injection training visits are scheduled within 48 hours from the time your patient receives his or her Acthar shipment from the Specialty Pharmacy. Staff from the Acthar Specialty Pharmacy will help to guide and expedite this process.
Will the nurse give my patient an actual injection?
No. The visiting nurse will provide direction on how to self-inject Acthar and answer any questions your patient may have about the injection process, but will not actually perform the injection.
Who can my patient call if he or she has questions?
Acthar patients or their care partners can call 1-877-463-88031-877-463-8803, Monday–Friday, 8 AM–8 PM ET and ask for assistance with in-home injection training services.

Acthar is indicated for severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: keratitis, iritis, iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, anterior segment inflammation.

Important Safety Information

SEE More


  • Acthar should never be administered intravenously
  • Administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of Acthar

Important Safety Information



  • Acthar should never be administered intravenously
  • Administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of Acthar
  • Acthar is contraindicated where congenital infections are suspected in infants
  • Acthar is contraindicated in patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction or sensitivity to proteins of porcine origins

Warning and Precautions

  • The adverse effects of Acthar are related primarily to its steroidogenic effects
  • Acthar may increase susceptibility to new infection or reactivation of latent infections
  • Suppression of the hypothalamic-pituitary-axis (HPA) may occur following prolonged therapy with the potential for adrenal insufficiency after withdrawal of the medication. Adrenal insufficiency may be minimized by tapering of the dose when discontinuing treatment. During recovery of the adrenal gland patients should be protected from the stress (e.g. trauma or surgery) by the use of corticosteroids. Monitor patients for effects of HPA suppression after stopping treatment
  • Cushing’s Syndrome may occur during therapy but generally resolves after therapy is stopped. Monitor patients for signs and symptoms
  • Acthar can cause elevation of blood pressure, salt and water retention, and hypokalemia. Blood pressure, sodium and potassium levels may need to be monitored
  • Acthar often acts by masking symptoms of other diseases/disorders. Monitor patients carefully during and for a period following discontinuation of therapy
  • Acthar can cause GI bleeding and gastric ulcer. There is also an increased risk for perforation in patients with certain gastrointestinal disorders. Monitor for signs of bleeding
  • Acthar may be associated with central nervous system effects ranging from euphoria, insomnia, irritability, mood swings, personality changes, and severe depression, and psychosis. Existing conditions may be aggravated
  • Patients with comorbid disease may have that disease worsened. Caution should be used when prescribing Acthar in patients with diabetes and myasthenia gravis
  • Prolonged use of Acthar may produce cataracts, glaucoma and secondary ocular infections. Monitor for signs and symptoms
  • Acthar is immunogenic and prolonged administration of Acthar may increase the risk of hypersensitivity reactions. Neutralizing antibodies with chronic administration may lead to loss of endogenous ACTH activity
  • There is an enhanced effect in patients with hypothyroidism and in those with cirrhosis of the liver
  • Long-term use may have negative effects on growth and physical development in children. Monitor pediatric patients
  • Decrease in bone density may occur. Bone density should be monitored for patients on long-term therapy
  • Pregnancy Class C: Acthar has been shown to have an embryocidal effect and should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus

Adverse Reactions

  • Common adverse reactions for Acthar are similar to those of corticosteroids and include fluid retention, alteration in glucose tolerance, elevation in blood pressure, behavioral and mood changes, increased appetite and weight gain
  • Specific adverse reactions reported in IS clinical trials in infants and children under 2 years of age included: infection, hypertension, irritability, Cushingoid symptoms, constipation, diarrhea, vomiting, pyrexia, weight gain, increased appetite, decreased appetite, nasal congestion, acne, rash, and cardiac hypertrophy. Convulsions were also reported, but these may actually be occurring because some IS patients progress to other forms of seizures and IS sometimes mask other seizures, which become visible once the clinical spasms from IS resolve

Other adverse events reported are included in the full Prescribing Information.

Please see full Prescribing Information.